• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Aranesp (darbopoetin alfa) For Injection


Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- May 2008

 

The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary.


Summary View

Sections Modified

PRECAUTIONS

  • Hematology
  • Patients Transitioning to Dialysis

ADVERSE REACTIONS

  • Chronic Renal Failure Patients
    • Adult Patients
      • Table 2
      • Table 3
    • Pediatric Patients

 

Label approved 05/05/2008 is not available on Drugs@FDA